Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.67 |
| ▸ | CCR6 | P51684 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | EBP | Q15125 | 1/20 | 0.40 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2017732 | 0.89 | CYP3A4 (0.69) | CYP3A4GPR119CYP2C9 | |
| SCHEMBL1129277 | 0.85 | CYP3A4 (0.64) | CYP3A4GPR119CYP2C9 | |
| SCHEMBL4368644 | 0.84 | CYP3A4 (0.68) | CYP3A4GPR119CYP2C9 | |
| SCHEMBL9006352 | 0.84 | CYP3A4 (0.79) | CYP3A4GPR119CYP2C9 | |
| SCHEMBL2019784 | 0.84 | CYP3A4 (0.79) | CYP3A4GPR119CYP2C9 | |
| SCHEMBL1128588 | 0.84 | CYP3A4 (0.70) | CYP3A4GPR119CYP2C9 | |
| SCHEMBL1128844 | 0.83 | CYP3A4 (0.84) | CYP3A4GPR119CYP2C9 | |
| SCHEMBL2022629 | 0.83 | CYP3A4 (0.64) | CYP3A4ALDH1A1GPR119MAPTCYP2C9 | |
| SCHEMBL1128328 | 0.83 | CYP3A4 (0.80) | CYP3A4KDM4EALDH1A1GPR119CYP2C9 | |
| SCHEMBL1128407 | 0.82 | CYP3A4 (0.79) | CYP3A4GPR119CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160222-A1 | MODULATORS OF GLUCOSE HOMEOSTASIS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX, INC. | 2011-06-30 | — | — | US | claimed |
| US-20110160222-A1 | MODULATORS OF GLUCOSE HOMEOSTASIS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX, INC. | 2011-06-30 | — | — | US | disclosed |
| US-20110160222-A1 | MODULATORS OF GLUCOSE HOMEOSTASIS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX, INC. | 2011-06-30 | — | — | US | disclosed |
| US-20110160222-A1 | MODULATORS OF GLUCOSE HOMEOSTASIS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX, INC. | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160222-A1 | MODULATORS OF GLUCOSE HOMEOSTASIS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | GPR119, GCKR, GID4 | CYP3A4 789/4885CCR6 4414/4885TSHR 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.